DK468388D0 - Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset - Google Patents

Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset

Info

Publication number
DK468388D0
DK468388D0 DK468388A DK468388A DK468388D0 DK 468388 D0 DK468388 D0 DK 468388D0 DK 468388 A DK468388 A DK 468388A DK 468388 A DK468388 A DK 468388A DK 468388 D0 DK468388 D0 DK 468388D0
Authority
DK
Denmark
Prior art keywords
complex
gylolol
weave
procedures
polyethylene
Prior art date
Application number
DK468388A
Other languages
English (en)
Other versions
DK468388A (da
Inventor
Jr Henry Berger
Salvatore Vincent Pizzo
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878719825A external-priority patent/GB8719825D0/en
Priority claimed from GB878723468A external-priority patent/GB8723468D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of DK468388D0 publication Critical patent/DK468388D0/da
Publication of DK468388A publication Critical patent/DK468388A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK468388A 1987-08-21 1988-08-19 Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset DK468388A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878719825A GB8719825D0 (en) 1987-08-21 1987-08-21 Complex
GB878723468A GB8723468D0 (en) 1987-10-06 1987-10-06 Complex

Publications (2)

Publication Number Publication Date
DK468388D0 true DK468388D0 (da) 1988-08-19
DK468388A DK468388A (da) 1989-02-22

Family

ID=26292631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK468388A DK468388A (da) 1987-08-21 1988-08-19 Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset

Country Status (6)

Country Link
EP (1) EP0304311A1 (da)
JP (1) JPS6471490A (da)
AU (1) AU611932B2 (da)
CA (1) CA1308377C (da)
DK (1) DK468388A (da)
NZ (1) NZ225880A (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2662311B2 (ja) * 1989-08-07 1997-10-08 デビオファルム ソシエテ アノニム 生物学的に活性な新規薬剤・ポリマー誘導体およびその製造方法
WO1991018630A1 (de) * 1990-05-30 1991-12-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Polyethersubstituierte tumormittel
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
DK0643772T3 (da) 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
GB8403656D0 (en) * 1984-02-11 1984-03-14 Vernon Carus Ltd Yarns
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds

Also Published As

Publication number Publication date
CA1308377C (en) 1992-10-06
EP0304311A1 (en) 1989-02-22
AU611932B2 (en) 1991-06-27
JPS6471490A (en) 1989-03-16
AU2142888A (en) 1989-03-02
DK468388A (da) 1989-02-22
NZ225880A (en) 1991-07-26

Similar Documents

Publication Publication Date Title
DK573384D0 (da) Sphingosinderivater, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende disse derivater
DK445084A (da) 6-flour-1,4-dihydro-4-oxo-7-substituerede piperazinylquinolin-3-carboxylsyrederivater, fremgangsmaade til fremstilling af samme og farcaceutiske sammensaetninger indeholdende samme
DK108888D0 (da) Farmaceutisk tablet, farmaceutisk granulat og fremgangsmaader til fremstilling af henholdsvis denne tablet og dette granulat
DK31784D0 (da) Phophorholdige amidforbindelser, farmaceutiske kompositioner indeholdende disse, og fremgangsmader til forbindelsernes fremstilling
NZ216306A (en) Pharmaceutical compositions containing tissue plasminogen activator
DK163173C (da) Fremgangsmaade til fremstilling af et lyofiliseret farmaceutisk praeparat af vaevs-plasminogenaktivator (t-pa)
DK277986D0 (da) Fremgangsmaade og turbosigte til vindsigtning af en udstroeet materialestroem, isaer cement
DK127588A (da) Beta-aminoethylsubstituerede phenylforbindelser, farmaceutiske praeparater indeholdende samme og fremgangsmaader til fremstilling af saadanne forbindelser
DK468388D0 (da) Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset
DK162221C (da) Cinnolinforbindelser, fremgangsmaade til fremstilling deraf og farmaceutiske midler indeholdende forbindelserne
DK102990A (da) Thieno-triazolodiazepinderivater, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
DK133587A (da) 2-heterocyclylthio-penemer, deres anvendelse og farmaceutisk komposition indeholdende forbindelserne
DK187989D0 (da) Substituerede propanaminer, fremgangsmaade til fremstilling heraf og laegemidler indeholdende saadanne forbindelser
DK612788A (da) Alkoxyderivater af ginkolider, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende saadanne forbindelser
DK617684A (da) 1,3-dioxolanylderivater, fremgangsmaade til deres fremstilling, deres anvendelse og laegemidler indeholdende disse forbindelser
DK93385D0 (da) 3-amino-1-(4,5,6,7-tetrahydro-benzothiazolyl)-2-pyrazoliner, fremgangsmaade til fremstilling af disse forbindelser og farmaceutiske praeparater indeholdende disse forbindelser
DK525187D0 (da) Imidazooe4,5-baapyridinon-2-derivater, fremgangsmaade til fremstilling af og laegemidler indeholdende saadanne derivater
DK507684A (da) Thiadiazinderivater, fremgangsmaader til deres fremstilling og farmaceutiske midler indeholdende disse thiadiazinderivater
DK365087A (da) 1,3,5-trithianderivater, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
DK95691D0 (da) Kompositprotese og fremgangsmaade til fremstilling af samme
DK39584D0 (da) Anvendelse af nafazatrom til forebyggelse og behandling af diverse sygdomme, laegemidler indeholdende nafazatrom sa mt fremgangsmader til disses fremstilling
DK176888A (da) Thieno-imidazo(2,1-b)thiazolderivater, fremgangsmaade til fremstilling af saadanne derivater og laegemiddel indeholdende disse
DK159685C (da) Imidazothienopyrimidiner, farmaceutiske praeparater indeholdende disse, en anvendelse af forbindelserne og fremgangsmaade til deres fremstilling
DK127086A (da) Substituerede 1,8-naphthyridoner, fremgangsmaader til deres fremstilling og farmaceutiske kompositioner, der indeholder disse forbindelser
DK339285D0 (da) Pyridinderivater, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende forbindelserne

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment